摘要
目的了解英夫利昔单抗治疗银屑病患者的安全性及疗效。方法回顾北京大学第三医院近3年住院治疗的应用英夫利昔单抗的银屑病患者病历,对其一般情况、病史、诊断、银屑病皮损面积和严重度评分(psoriasis area and severity index,PASI)、治疗反应进行总结。英夫利昔单抗给药方法为静脉输液,约5 mg/kg,分别在0、2、6、14周各给药1次,以后依病情予以调整,每8周或更长时间给药1次。结果共30例银屑病患者应用英夫利昔单抗治疗,包括斑块型银屑病25例(3例合并关节炎),红皮病型银屑病5例(2例合并关节炎)。男21例,女9例。基线PASI中位数20.7分(10.4分,27.7分)。23例患者完成了14周的治疗,PASI 90/75/50应答率分别为43.48%/69.57%/86.96%。19例患者完成了54周的随访,PASI 90/75/50应答率分别为31.58%/52.63%/78.95%。随访时间最长的患者为118周时共接受了10次治疗,可维持在PASI 90。所有患者药物使用时间中位数46周(6周,83周),住院次数中位数6次(3次,10次),住院时长中位数1 d(1 d,1 d),单次住院费用中位数16 000.40元(2 650.11元,21 749.13元)。不良事件8例(26.67%),其中1例既往有结核感染的患者出现了结核的活动。结论英夫利昔单抗治疗银屑病疗效确切,总体安全性尚可。
Objective To evaluated the safety and efficacy of infliximab in the treatment of psoriasis. Methods The medical records of all psoriasis inpatients treated with infliximab during the past three years in Peking University Third Hospital were reviewed. Patient characteristics, disease history, diagnosis, psoriasis area and severity index(PASI) and treatment response were analyzed. Infliximab was given by intravenous infusion at a dose of approximately 5 mg/kg at 0, 2, 6 and 14 weeks, and every 8 weeks or longer thereafter adjusted according to the condition of the patient. Results A total of 30 patients were treated with infliximab, including 25 cases of plaque psoriasis(3 cases with arthritis) and 5 cases of erythrodermic psoriasis(2 cases with arthritis). There were 21 males and 9 females. The median baseline PASI was 20.7(10.4, 27.7). Twenty-three patients completed 14 weeks of treatment, and the PASI 90/75/50 response rates were 43.48%/69.57%/86.96%, respectively. Nineteen patients completed 54 weeks of follow-up and the PASI 90/75/50 response rates were 31.58%/52.63%/78.95%, respectively. The patient with the longest follow-up period of 118 weeks received a total of 10 treatments and could remain at PASI 90. The median duration of drug use for all patients was 46 weeks(6 weeks, 83 weeks). The median number of hospitalization was 6(3, 10). The median length of hospital stay was 1 day(1 day, 1 day). The median cost of hospitalization was $16 000.40($2 650.11,$21 749.13). The incidence of adverse events was 8 cases(26.67%), including one patient with previous tuberculosis infection developing active tuberculosis.Conclusion Infliximab is effective and relatively safe in the treatment of psoriasis.
作者
郭金竹
王文慧
叶珍珍
关欣
胡建刚
谢志强
张春雷
GUO Jinzhu;WANG Wenhui;YE Zhenzhen;GUAN Xin;HU Jiangang;XIE Zhiqiang;ZHANG Chunlei(Department of Dermatology,Peking University Third Hospital,Beijing 100191,China;Department of Dermatology,Peking University Third Hospital Yanqing Hospital,Beijing 102100,China)
出处
《中国皮肤性病学杂志》
CAS
CSCD
北大核心
2019年第3期265-269,共5页
The Chinese Journal of Dermatovenereology
基金
中国医疗保健国际交流促进会-LEO皮肤研究基金(80446-06)
作者简介
通讯作者:王文慧,E-mail:wwh0608@126.com
